IP Library Granted Patent US 10,987,415
Granted Patent B2
US 10,987,415 · App. 16/061,853 · Granted Apr 27, 2021

Process for production of purified recombinant cholera toxin B (rCTB) and formulation thereon

Inventors: Tarun Sharma (New Delhi, IN); Neeraj Joshi (New Delhi, IN); Vibhu Kanchan (New Delhi, IN); Deepa Sikriwal (New Delhi, IN); Nidhi Shukla (Ghaziabad, IN); Davinder Gill (New Delhi, IN)
Assignee: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.
A61K39/107A61P31/04C07K14/28C12P1/04C12P21/02A61K2039/521C12N1/20C12N15/86
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,987,415
App. No.
16/061,853
Granted
Apr 27, 2021
Kind
B2
Abstract

The present invention relates to a novel process of production of purified recombinant cholera toxin B (rCTB) which provides protection against diarrhea caused by various bacteria such as Vibrio cholerae and Enterotoxigenic Escherichia coli (ETEC). More particularly, the present invention relates to a process of production of rCTB with significantly higher yield and higher purity. The present invention also relates to a vaccine formulation having synergistic protection against Vibrio cholerae and cross protection against ETEC.

Claims (23)

1. A novel process for producing purified recombinant cholera toxin B (rCTB) from Vibrio cholerae and formulating the purified rCtB to obtain a novel vaccine formulation, said process comprising the steps of

fermentating an rCTB producing Vibrio cholerae strain to obtain a fermented culture;

heat inactivating the fermented culture to obtain a harvest of partially purified rCTB;

purifying said harvest to obtain purified rCTB; and

formulating the purified rCTB to produce the novel vaccine formulation,

wherein said fermented culture is subjected to a step of heat inactivating at a temperature range of 65° C.±5° C. for 30±15 mins, followed by centrifugation to pellet out inactivated cells and denatured contaminating proteins; wherein the post centrifugation supernatant contains more than 70% pure rCTB, and wherein this partially purified rCTB is further purified by precipitation and tangential flow filtration to yield more than 90-95% pure rCTB.

2. The process as claimed in claim 1 wherein said yields are in the range of 1.5-2.5 gm/litre and purity of the purified, rCTB is higher than 95% (>95%).

3. The process as claimed in claim 1 wherein said fermentation step comprises of following steps:

(a) inoculating an rCTB producing Vibrio cholerae strain into rCTB production media in a fermenter at predefined conditions;

(b) running the fermenter at a predetermined pH and a predetermined temperature for a predetermined duration of time to obtain the fermented culture.

4. The process as claimed in claim 3 wherein said predefined conditions include addition of feed containing 1M glucose to the fermenter media.

5. The process as claimed in claim 3 wherein said predetermined pH is in the range of 7.2-7.5, said predetermined temperature is in the range of 35−37° C., and said predetermined duration of time ranges from 18-22 hrs.

6. A novel process for producing purified recombinant cholera toxin B (rCTB) from Vibrio cholerae and formulating the purified rCtB to obtain a novel vaccine formulation, said process comprising the steps of

fermentating an rCTB producing Vibrio cholerae strain to obtain a fermented culture;

heat inactivating the fermented culture to obtain a harvest of partially purified rCTB;

purifying said harvest to obtain purified rCTB; and

formulating the purified rCTB to produce the novel vaccine formulation, wherein the purifying step is performed without chromatography, wherein said fermented culture is subjected to a step of heat inactivating at a temperature range of 65° C.±5° C. for 30±15 mins, followed by centrifugation to pellet out inactivated cells and denatured contaminating proteins; wherein the post centrifugation supernatant contains more than 70% pure rCTB, and wherein this partially purified rCTB is further purified by precipitation and tangential flow filtration to yield more than 90-95% pure rCTB.

7. The process as claimed in claim 6 wherein said yields are in the range of 1.5-2.5 gm/litre and purity of the purified, rCTB is higher than 95% (>95%).

8. The process as claimed in claim 6 wherein said fermentation step comprises of following steps:

(c) inoculating an rCTB producing Vibrio cholerae strain into rCTB production media in a fermenter at predefined conditions;

(d) running the fermenter at a predetermined pH and a predetermined temperature for a predetermined duration of time to obtain the fermented culture.

9. The process as claimed in claim 8 wherein said predefined conditions include addition of feed containing 1M glucose to the fermenter media.

10. The process as claimed in claim 8 wherein said predetermined pH is in the range of 7.2-7.5, said predetermined temperature is in the range of 35−37° C., and said predetermined duration of time ranges from 18-22 hrs.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 18, 2018
From: SHARMA, TARUN; JOSHI, NEERAJ; KANCHAN, VIBHU; SIKRIWAL, DEEPA; SHUKLA, NIDHI; GILL, DAVINDER, DR.
To: MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.
Reel/Frame 046378/0442 →
Priority Claims (1)
IN 4089/DEL/2015 · Dec 14, 2015 · national
Continuity (1)
Related Publication 20180360944A1 · Dec 20, 2018